Home » Market News » DirectorsTalk Highlights » Looking into the Future with Lupus
Immupharma Plc

Looking into the Future with Lupus

They say the only things guaranteed in life are death and taxes. I am lucky enough to add one more certainty to the list: lupus. Ironically, being certain about lupus only means being entirely uncertain about everything else in my life.

When someone asks what my life will look like in five years, I do not respond with what it might look like realistically, I tell them about my dream. It’s not that I want to be dishonest; I don’t. But being honest means admitting that my doctor and I are uncertain what the road ahead looks like, and the few details I am able to predict aren’t likely to lead to a fairy tale happy ending.

 

ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.